MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference…
MaaT PharmaNovember 2, 2023
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial…
MaaT PharmaOctober 26, 2023
MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Kepler…
MaaT PharmaOctober 9, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaOctober 6, 2023
MaaT Pharma Announces Poster Presentations at the 38th Annual Meeting of the Society for Immunotherapy…
MaaT PharmaSeptember 27, 2023
MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update The ARES…
MaaT PharmaSeptember 26, 2023
MaaT Pharma and Skyepharma Complete Construction of Europe's Largest Manufacturing Facility for Microbiome Ecosystem Therapies…
MaaT PharmaSeptember 12, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaSeptember 8, 2023
MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation Aiming to Improve Overall…
MaaT PharmaSeptember 7, 2023
